Background and objectives: Malnutrition associated with anemia remains a leading cause of morbidity and mortality among Adivasi children in India. The present trial aimed to test three possible ways of designing improved supplementary meals and to define their role in decreasing rates of anemia, thus increasing hemoglobin (Hb) concentrations as primary health objective: diversified meals only (intervention group 1 (IG 1)), with the addition of locally producible Amaranthus tricolor/Moringa oleifera leaf powders (ALP/MLP) in the ratio 2:1 (IG2) or with an adjusted amount of commercially produced micronutrient powder TopNutri (IG3). Methods: Cluster-randomization of 21 villages resulted in the inclusion of n=293 children aged 6-39 months after baseline assessment. The trial duration was 18 months, beginning in February 2015 (baseline assessment), with application of study meals three times a week at community level. Anthropometric, Hb (HemoCue201+) and morbidity data were collected in a total of four assessment points. At baseline a socio-economic questionnaire was performed. Results: Adjusted for age and Hb concentrations at baseline, time between assessment points, and gender; IG1 showed significant higher Hb concentrations as compared to the control group (CG) throughout the intervention period. The Hb of the remaining intervention groups IG2 or IG3, remained comparable to the CG at all assessment points. The effect on growth indices was less consistent, however most positive tendencies related to nutrition status (stunting, underweight, wasting) and morbidity reduction were attributable to IG3, indicating the beneficial role of a holistic nutrient composition in addressing undernutrition and infectious diseases. Conclusion: This low-dose intervention trial proofed the feeding of diversified diets alone (IG1) to be sufficient to significantly increase Hb concentrations of study children. On the way of achieving diversified diets for Santal children the promotion of kitchen garden programs combined with interactive awareness trainings may be a key measure. Trial registration: the trial was retrospectively registered at the German Clinical Trials Register on the 1 st July 2019 (DRKS00017388). URL: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00017388